Floatz logo

azd6738

Solid Tumour Refractory to Conventional Treatment

Royal Marsden NHS Foundation TrustPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

181 Active assets in the Solid Tumour Refractory to Conventional Treatment cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
CatalYm GmbH
Phase 2BB

View all 50 →

Same molecule, other indications

azd6738 is also rated in:

small cell lung carcinomaDormant
B
Indicative ·
62 / 100
View asset →
squamous cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →
adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →